Janney Montgomery Scott LLC Boosts Position in Boston Scientific Corporation $BSX

Key Points

• Janney Montgomery Scott LLC increased its stake in Boston Scientific Corporation by 4.4% during Q2, holding approximately 297,960 shares valued at $32 million.
• Boston Scientific reported a quarterly earnings per share of $0.75, beating estimates, with a revenue of $5.06 billion, up 22.8% year-over-year.
• A number of analysts upgraded Boston Scientific's stock ratings, with price targets rising to as high as $132.00 and a consensus rating of "Buy".

Janney Montgomery Scott LLC raised its stake in shares of Boston Scientific Corporation (NYSE:BSX - Free Report) by 4.4% in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 297,960 shares of the medical equipment provider's stock after buying an additional 12,497 shares during the quarter. Janney Montgomery Scott LLC's holdings in Boston Scientific were worth $32,004,000 at the end of the most recent reporting period.

Other hedge funds have also added to or reduced their stakes in the company. GAMMA Investing LLC boosted its position in shares of Boston Scientific by 15.4% during the 2nd quarter. GAMMA Investing LLC now owns 29,486 shares of the medical equipment provider's stock valued at $3,167,000 after acquiring an additional 3,932 shares during the last quarter. Bank of New Hampshire boosted its position in shares of Boston Scientific by 552.0% during the 2nd quarter. Bank of New Hampshire now owns 19,724 shares of the medical equipment provider's stock valued at $2,119,000 after acquiring an additional 16,699 shares during the last quarter. NS Partners Ltd boosted its position in shares of Boston Scientific by 1.6% during the 1st quarter. NS Partners Ltd now owns 368,189 shares of the medical equipment provider's stock valued at $37,143,000 after acquiring an additional 5,704 shares during the last quarter. MRA Advisory Group bought a new stake in shares of Boston Scientific during the 2nd quarter valued at about $273,000. Finally, Neville Rodie & Shaw Inc. boosted its position in shares of Boston Scientific by 95.9% during the 2nd quarter. Neville Rodie & Shaw Inc. now owns 45,460 shares of the medical equipment provider's stock valued at $4,883,000 after acquiring an additional 22,255 shares during the last quarter. Hedge funds and other institutional investors own 89.07% of the company's stock.

Boston Scientific Stock Performance

Shares of BSX stock opened at $95.78 on Thursday. The company has a debt-to-equity ratio of 0.49, a quick ratio of 0.82 and a current ratio of 1.37. Boston Scientific Corporation has a fifty-two week low of $80.64 and a fifty-two week high of $109.50. The stock has a 50 day moving average price of $103.30 and a two-hundred day moving average price of $102.08. The company has a market capitalization of $141.91 billion, a P/E ratio of 57.01, a PEG ratio of 2.35 and a beta of 0.61.

Boston Scientific (NYSE:BSX - Get Free Report) last announced its quarterly earnings data on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share for the quarter, beating the consensus estimate of $0.72 by $0.03. Boston Scientific had a return on equity of 19.21% and a net margin of 13.55%.The firm had revenue of $5.06 billion during the quarter, compared to the consensus estimate of $4.89 billion. During the same quarter in the previous year, the company posted $0.62 earnings per share. The business's revenue was up 22.8% on a year-over-year basis. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. Analysts expect that Boston Scientific Corporation will post 2.85 earnings per share for the current year.

Analyst Ratings Changes

A number of analysts have recently issued reports on BSX shares. Leerink Partnrs upgraded Boston Scientific to a "strong-buy" rating in a research report on Monday, June 16th. Leerink Partners lifted their price target on Boston Scientific from $127.00 to $128.00 and gave the company an "outperform" rating in a research report on Wednesday. Robert W. Baird lifted their price target on Boston Scientific from $123.00 to $128.00 and gave the company an "outperform" rating in a research report on Wednesday. Oppenheimer upgraded Boston Scientific from a "market perform" rating to an "outperform" rating and boosted their target price for the stock from $118.00 to $125.00 in a research report on Monday, September 8th. Finally, Canaccord Genuity Group boosted their target price on Boston Scientific from $131.00 to $132.00 and gave the stock a "buy" rating in a research report on Wednesday. Three research analysts have rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and one has assigned a Hold rating to the company's stock. According to MarketBeat, Boston Scientific has a consensus rating of "Buy" and a consensus price target of $120.67.

Insider Buying and Selling

In other Boston Scientific news, EVP Joseph Michael Fitzgerald sold 50,000 shares of the business's stock in a transaction that occurred on Wednesday, October 1st. The stock was sold at an average price of $98.47, for a total value of $4,923,500.00. Following the completion of the sale, the executive vice president owned 178,342 shares in the company, valued at approximately $17,561,336.74. The trade was a 21.90% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Arthur C. Butcher sold 17,313 shares of the business's stock in a transaction that occurred on Friday, August 1st. The shares were sold at an average price of $104.63, for a total value of $1,811,459.19. Following the completion of the sale, the executive vice president owned 23,600 shares of the company's stock, valued at $2,469,268. The trade was a 42.32% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 174,214 shares of company stock worth $17,972,457. Company insiders own 0.50% of the company's stock.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.

Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Corporation (NYSE:BSX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.